Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8N6M0
UPID:
OTU6B_HUMAN
Alternative names:
DUBA-5; OTU domain-containing protein 6B
Alternative UPACC:
Q8N6M0; A8K6I1; B4DEY0; Q9NTA4; Q9Y387
Background:
Deubiquitinase OTUD6B, also known as DUBA-5 and OTU domain-containing protein 6B, plays a crucial role in cellular processes including protein synthesis regulation and DNA synthesis repression. It is involved in the ubiquitin-dependent regulation downstream of mTORC1, potentially affecting protein synthesis initiation and proteasome assembly.
Therapeutic significance:
The protein is linked to Intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies, a severe multisystem disorder. Understanding the role of Deubiquitinase OTUD6B could open doors to potential therapeutic strategies for this and related conditions.